Skip to main content
. 2023 Oct 13;37(12):2395–2403. doi: 10.1038/s41375-023-02061-1

Table 1.

Baseline patient characteristics with respect to IKZF1 mutation status.

Parameter IKZF1 mutated IKZF1 wildtype p
n/N (%) 45/1606 (2.8) 1561/1606 (97.2)
Age (years), median (IQR) 52 (43–64) 56 (45–66) 0.501
Sex, n (%) 0.762
 Female 20 (44.4) 748 (47.9)
 Male 25 (55.6) 813 (52.1)
Disease status, n (%)
  de novo 32 (71.1) 1307 (83.7) 0.038
  sAML 9 (20.0) 186 (11.9) 0.107
  tAML 2 (4.4) 52 (3.3) 0.662
  Missing 2 (4.4) 61 (3.9)
Extramedullary disease, n (%) 10 (22.2) 204 (13.1) 0.116
 missing 3 (6.7) 137 (8.8)
ELN-Risk 2022, n (%)
  Favorable 10 (22.2) 566 (36.3) 0.079
  Intermediate 8 (17.8) 411 (26.3) 0.297
  Adverse 26 (57.8) 567 (36.3) 0.004
  Missing 1 (2.2) 17 (1.1)
Complex karyotype, n (%) 0.479
 No 36 (80.0) 1283 (82.2)
 Yes 7 (15.6) 181 (11.6)
 Missing 2 (4.4) 97 (6.2)
Normal karyotype, n (%) 0.003
 No 29 (64.5) 644 (41.3)
 Yes 14 (31.1) 819 (52.4)
 Missing 2 (4.4) 98 (6.3)
Allogeneic stem cell transplantation
  In first CR 6 (13.3) 238 (15.2) 0.836
  As salvage therapy 10 (22.2) 213 (13.6) 0.123
  Other 2 (4.4) 50 (3.2) 0.655
  Missing 0 0
Laboratory, median (IQR)
  WBC (109/l) 17.8 (5.0–43.0) 19.1 (4.4–53.7) 0.590
  HB (mmol/l) 5.3 (4.7–6.7) 5.9 (5.1–7.0) 0.036
  PLT (109/l) 35 (25–80) 51 (28–95) 0.029
  LDH (U/l) 523.2 (287.0–751.0) 443.7 (281.0–778.0) 0.694
  PBB (%) 45.5 (16.5–81.0) 40.0 (12.0–73.0) 0.150
  BMB (%) 65.0 (43.0–80.5) 63.0 (44.0–79.0) 0.997

Bold typing indicates statistical significance (p < 0.05).

AML acute myeloid leukemia, sAML secondary AML, tAML therapy-associated AML, BMB bone marrow blasts, HB hemoglobin, IQR interquartile range, n/N number, PBB peripheral blood blasts, PLT platelet count, WBC white blood cell count. Bold typing indicates statistical significance.